Researcher
Sandra Tuyaerts
- Keywords (Vrije Universiteit Brussel):Medicine
- Disciplines (Vrije Universiteit Brussel):Cancer biology, Cancer therapy, Immunology not elsewhere classified
- Disciplines (KU Leuven):Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
- See also: Sandra Tuyaerts (KU Leuven)
Affiliations
- Laboratory for Medical and Molecular Oncology (Research group)
Member
From1 Nov 2022 → Today - Medical Oncology (Department)
Member
From1 May 2020 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → 20 Oct 2022 - Clinical sciences (Department)
Member
From1 Jun 2020 → Today - Clinical sciences (Department)
Member
From1 Jun 2020 → 20 Oct 2022 - Gynaecological Oncology (Division)
Member
From16 Nov 2009 → 31 Dec 2022 - Physiology (Department)
Member
From1 Oct 1999 → 30 Apr 2008 - Physiology (Department)
Member
From1 Oct 1999 → 30 Apr 2008
Projects
1 - 1 of 1
- Exploring the mechanisms of RESponse and RESistance to novel Cancer immunotherapies in tumors Unresponsive to Earlier immune checkpoint inhibitionFrom1 Jan 2022 → TodayFunding: FWO EOS
Publications
1 - 10 of 21
- Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma(2024)
Authors: Jens Tijtgat, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze, Steven Raeymaeckers, Ramses Forsyth, Ivan Van Riet, et al.
- Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives(2023)
Authors: Johnny Duerinck, Sandra Tuyaerts, Kiavash Movahedi, Bart Neyns
- Current "state of the art" on dendritic cell-based cancer vaccines in melanoma(2023)
Authors: Julia Katharina Schwarze, Xenia Geeraerts, Sandra Tuyaerts, Bart Neyns
Pages: 87-93 - Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma(2023)
Authors: Emiel A De Jaeghere, Sandra Tuyaerts, An Van Nuffel, Ann Belmans, Kris Bogaerts, Regina E. M. Baiden-Amissah, Lien Lippens, Peter Vuylsteke, Stéphanie Henry, xuan bich trinh, et al.
Pages: 475-491 - Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients(2022)
Authors: Julia Katharina Schwarze, Jens Tijtgat, Gil Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, et al.
Pages: 1-13 - Trial watch(2022)
Authors: Raquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel M Borras, Jannes Govaerts, Stefan Naulaerts, Zwi N Berneman, Benoit Beuselinck, Kalijn F Bol, Jannie Borst, et al.
- Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells(2021)
Authors: Jens Tijtgat, Jolien De Munck, Inès Dufait, Julia Katharina Schwarze, Ivan Van Riet, Lorenzo Franceschini, Karine Breckpot, Joeri L Aerts, Bart Neyns, Sandra Tuyaerts
- Endometrial Cancer Molecular Characterization(2021)
Authors: Regina Esi Mensimah Baiden-Amissah, Daniela Annibali, Sandra Tuyaerts, Frederic Amant
- Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma(2021)
Authors: Wout De Wispelaere, Daniela Annibali, Sandra Tuyaerts, Diether Lambrechts, Frédéric Amant
- Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors(2020)
Authors: Julia Katharina Schwarze, Gil Awada, Louise Cras, Jens Tijtgat, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns
Pages: 1-16